Veradigm

About Veradigm

Financials

Dated, source-cited figures. Estimates are marked.

Products by Veradigm

All products by Veradigm reviewed by our AI panel of experts.

VeradigmAI Healthcare

Healthcare technology connecting providers, payers, and life sciences

From $49/mo6.5/10

How Our Review Panel Scores Veradigm

Six independent reviewer personalities assessed Veradigm's product on their own terms. They disagreed by 1.4 points — The Finance Lead was the hardest to convince, The Power User the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Veradigm competes with, and how they differ.

a

athenahealth

athenahealth competes directly in ambulatory EHR and practice management with a cloud-native, single-instance platform and a network-effect pricing model, versus Veradigm's licensed/subscription EHR business plus separate payer and life-sciences data segments.

K

Komodo Health7.6/10

Komodo Health sells real-world healthcare data and analytics (its "Healthcare Map") to life sciences and payer clients, competing for the same budgets as Veradigm's Life Science segment, but aggregates claims and multi-source data rather than capturing it at the point of care through an owned EHR.

1 product reviewed on TopReviewed

I

IQVIA

IQVIA is a far larger (~$15B revenue) life-sciences data, technology and clinical-research company whose real-world-data offerings compete with Veradigm's EHR-derived data business, backed by broader commercial reach and a global research/consulting arm Veradigm does not have.

Flatiron Health8.2/10

Flatiron Health, owned by Roche, is the market leader in oncology-specific real-world data drawn from its own oncology EHR and clinic network, competing narrowly with Veradigm's life-sciences data business in cancer analytics rather than across Veradigm's broader ambulatory and payer scope.

1 product reviewed on TopReviewed

Company Timeline

Key milestones in Veradigm's history, with sources.

1. May 26, 2026Milestone

   Files comprehensive FY2023 and FY2024 Form 10-K, clearing most of its multi-year filing backlog

   Veradigm filed a combined Annual Report on Form 10-K for fiscal years 2023 and 2024, reporting GAAP revenue of $626.0M (2023) and $594.4M (2024) and a $291.6M net loss for 2024, a further milestone in its multi-year effort to become current with the SEC after its 2024 Nasdaq delisting.

   sec.gov
2. Feb 25, 2026Milestone

   SEC closes its investigation into Veradigm's revenue-recognition failures without recommending enforcement action

   The SEC notified Veradigm it had concluded its investigation into the company's prior revenue-recognition misstatements and did not plan to recommend enforcement action; former CEO Richard Poulton and former CFO Leah Jones, who resigned in December 2023, received similar letters.

   healthcaredive.com
3. Aug 18, 2025Milestone

   Board appoints Don Trigg, former Cerner president and Apree Health CEO, as new Chief Executive Officer

   Veradigm's board named Don Trigg, previously president of Cerner and CEO of Apree Health, as CEO effective September 2, 2025, succeeding interim CEO Tom Langan amid the company's ongoing financial-reporting remediation.

   healthcaredive.com
4. Mar 18, 2025Milestone

   Files long-delayed fiscal 2022 Form 10-K with restated 2020-2022 financial statements

   Nearly two years after first flagging the problem, Veradigm filed its fiscal 2022 Annual Report, reporting restated full-year revenue of $588 million and an $86.4 million net loss, plus restated 2020 and 2021 financials.

   healthcaredive.com
5. Jan 30, 2025Milestone

   Board ends strategic review of a possible sale without a transaction; shares fall about 40%

   After entering confidentiality agreements with more than 30 parties and receiving preliminary interest from five bidders following a May 2024 review announcement, Veradigm's board unanimously ended the strategic-alternatives process without a final sale proposal, and the stock fell roughly 40% on the news.

   investing.com
6. Feb 28, 2024Milestone

   Nasdaq issues delisting determination; shares suspended and move to the OTC Expert Market

   Nasdaq delisted Veradigm for failing to file timely periodic reports (2022 10-K and 2023 10-Qs) and for not holding a timely annual shareholder meeting; trading was suspended and the stock began trading over-the-counter under ticker MDRX.

   finance.yahoo.com
7. Sep 20, 2023Milestone

   Receives Nasdaq notice that it will be delisted for failing to timely file its 2022 10-K and two 2023 10-Qs

   Nasdaq notified Veradigm of noncompliance with Listing Rule 5250(c)(1) after the company failed to file its FY2022 Form 10-K and Q1/Q2 2023 Form 10-Qs within a previously granted 180-day exception period; Veradigm said it intended to appeal.

   sec.gov
8. Mar 22, 2023Milestone

   Board determines FY2021 and interim 2021-2022 financial statements can no longer be relied upon

   Veradigm disclosed that internal control failures tied to a revenue-recognition software tool implemented for ASC 606 compliance caused duplicate transactions and other errors, producing an estimated $40 million aggregate revenue misstatement across 2021 and 2022 and triggering a restatement.

   sec.gov
9. Jan 3, 2023Milestone

   Allscripts Healthcare Solutions renames itself Veradigm Inc., effective January 1, 2023

   Following a portfolio cleanup that made its Veradigm data and technology segment the core of the business, Allscripts completed its brand transition and formally changed its corporate name to Veradigm Inc. (Nasdaq: MDRX).

   healthcaredive.com
10. Mar 2, 2022Milestone

    Agrees to sell its Hospitals & Large Physician Practices business segment to Harris for up to $700 million

    Allscripts (later Veradigm) agreed to sell the net assets of its Hospitals & Large Physician Practices segment - including the Sunrise, Paragon, TouchWorks, Opal and dbMotion products - to N. Harris Computer Corporation, a subsidiary of Constellation Software, for up to $700 million, refocusing the company on its Veradigm data and technology business.

    sec.gov